2021/22流感季疫苗接种:英国数据关联检测阴性病例对照研究评估需急诊治疗的流感疫苗有效性及基层患者血清学分析
英国2021/22流感季采用检测阴性设计,评估1-17岁儿童和50岁以上成人接种疫苗对实验室确诊流感相关急诊就诊的有效性,并对接种与未接种成人进行血凝抑制试验血清学分析。儿童调整后疫苗有效性为72.7%(95%CI 52.7,84.3%),成人有效性有限为26.1%(95%CI 4.5,42.8%)。
要点
- 儿童接种流感疫苗对需急诊治疗的流感保护良好,调整后有效性72.7%。
- 成人疫苗有效性有限,调整后有效性26.1%,其中A(H1N1)为81%、A(H3N2)为33%。
- 对循环A(H3N2)株,当季接种成人抗体滴度≥1:40的比例为61%,未接种者为17%。
核心结论
- 儿童接种流感疫苗对需急诊治疗的流感有良好保护,成人有效性有限,A(H1N1)有效性高于A(H3N2)。
研究设计与样本
- 采用检测阴性病例对照设计,在哨点实验室监测系统中识别病例与对照,疫苗史来自国家免疫管理服务登记系统并与急诊就诊记录关联。
- 成人纳入423份阳性样本和32,917份阴性样本,儿童纳入145份阳性样本和6,438份阴性样本。
主要发现
- 儿童调整后疫苗有效性为72.7%(95%CI 52.7,84.3%),成人为26.1%(95%CI 4.5,42.8%)。
- 成人A(H1N1)疫苗有效性为81%(95%CI 50,93%),A(H3N2)为33%(95%CI 6,53%)。
- 对循环A(H3N2) A/Bangladesh/4005/2020-like株,当季接种成人抗体滴度≥1:40的比例为61%,2020/21或2021/22未接种者为17%(p<0.001)。
- 学龄前、小学和中学年龄段儿童均观察到一致的保护。
临床怎么用
- 儿童接种流感疫苗对需急诊治疗的流感保护良好,成人有效性有限,A(H1N1)有效性高于A(H3N2)。
局限性
- 不完美的检测特异性结合极低流行率可能使估计值偏向无效。
- 由于流感流行有限,研究无法确定不同疫苗类型间的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present England 2021/22 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related emergency care use in children aged 1-17 and in adults aged 50+, and serological findings in vaccinated vs unvaccinated adults by hemagglutination inhibition assay. Influenza vaccination has been routinely offered to all children aged 2-10 years and adults aged 65 years + in England. In 2021/22, the offer was extended to children to age 15 years, and adults aged 50-64 years. Influenza activity rose during the latter half of the 2021/22 season, while remaining comparatively low due to COVID-19 pandemic control measures. Influenza A(H3N2) strains predominated. A test negative design was used to estimate aVE by vaccine type. Cases and controls were identified within a sentinel laboratory surveillance system. Vaccine histories were obtained from the National Immunisation Management Service (NIMS), an influenza and COVID-19 vaccine registry. These were linked to emergency department presentations (excluding accidents) with respiratory swabbing ≤ 14 days before or ≤ 7 days after presentation. Amongst adults, 423 positive and 32,917 negative samples were eligible for inclusion, and 145 positive and 6,438 negative samples among children. Those admitted to hospital were further identified. In serology against the circulating A(H3N2) A/Bangladesh/4005/2020-like strain, 61 % of current season adult vaccinees had titres ≥ 1:40 compared to 17 % of those unvaccinated in 2020/21 or 2021/22 (p < 0.001). We found good protection from influenza vaccination against influenza requiring emergency care in children (72.7 % [95 % CI 52.7, 84.3 %]) and modest effectiveness in adults (26.1 % [95 % CI 4.5, 42.8 %]). Adult VE was higher for A(H1N1) (81 % [95 % CI 50, 93 %]) than A(H3N2) (33 % [95 % CI 6, 53 %]). Consistent protection was observable across preschool, primary and secondary school aged children. Imperfect test specificity combined with very low prevalence may have biased estimates towards null. With limited influenza circulation, the study could not determine differences by vaccine types.
引用
- Whitaker HJ, Hassell K, Hoschler K, et al. Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients. Vaccine. 2024. PMID: 38342716. doi:10.1016/j.vaccine.2024.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。